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Background: Head and neck cancers (HNC) are aggressive tumours. Overexpression of p16 in HNC correlates with human
papilloma virus (HPV)-associated HNC that carry a better prognosis than HPV-negative tumours. Angiogenesis is an important
factor in tumour progression. Our aim was to dissect the impact of p16 expression on angiogenesis factors in HNC.
Methods: Eighteen newly diagnosed HNC patients and controls were analysed. Eleven pro- and anti-angiogenesis factors were
quantified using multiplex ELISA in HNC patients and controls. Angiogenesis factors were analysed in tumour tissue using
immunohistochemistry.
Results: Circulating levels of endostatin (anti-angiogenesis factor) were higher in the HNC group compared with healthy donors.
Interestingly, the pro-angiogenesis factors angiopoietin-1 and vascular endothelial growth factor (VEGF) were significantly higher
in patients with p16-negative compared with p16-positive HNC. Moreover, the major source of VEGF in p16-positive HNC tissue
was tumour stromal cells. In contrast, both tumour cells and stromal cells expressed VEGF in p16-negative tissue.
Conclusions: We show that p16-negative tumours associate with increased circulating levels of pro-angiogenic VEGF and
angiopoietin-1. Tissue expression of VEGF differs between p16-positive and p16-negative tumours. These findings may explain
differences in the biological behaviour of p16-positive and p16-negative HNC. Better understanding of mechanisms by which the
p16 status influences tumour angiogenesis may guide the development of targeted therapies.
Head and neck cancer (HNC) constitutes an important proportion
of cancers worldwide. These are aggressive tumours, and survival
rates have remained poor in spite of advances in surgical
techniques, radiotherapy and chemotherapy. Interestingly, certain
subtypes of HNC are associated with a better prognosis. Sixty per
cent of oropharyngeal cancers associate with the oncogenic human
papilloma virus (HPV; subtypes 16 and 18; Venuti et al, 2004). Of
note, this cohort of patients has a better disease-free survival than
the patients who do not express the viral protein (Ang et al, 2010).
The reasons underlying this are not known, and further under-
standing of the biology of these tumours is necessary in order to
develop new therapeutic options.
It is well known that tumour growth depends on the establish-
ment of a robust vascular supply to support the oxygen and
nutrient requirements of cancer cells. This formation of blood
vessel network or angiogenesis also acts as a conduit to allow the
spread of cancer cells to the rest of the body (metastases) and
thereby promote aggressive tumour progression (Folkman et al,
1989; Hanahan and Folkman, 1996). Vessel turnover in healthy
tissue is maintained in the steady state by interactions between
molecules that promote angiogenesis (pro-angiogenesis factors)
and those that inhibit it (anti-angiogenesis factors; Hanahan and
Weinberg, 2011). Tumours exploit this phenomenon and can
produce a wide variety of pro-angiogenesis factors to promote their
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own growth, and the levels of these factors in the tumour
microenvironment could determine the outcome of cancer therapy.
Indeed, anti-angiogenesis therapies in the form of antibodies (for
example, anti-vascular endothelial growth factor (VEGF) antibody)
or recombinant proteins (for example, endostatin) are being
actively used in the treatment of solid tumours (Cohen et al, 2009;
Ye et al, 2014).
The aim of this work was to dissect the impact of prognostic
factors such as p16, tumour size and nodal status on the
angiogenesis profile of HNC. To this purpose, we studied the
circulating levels of a panel of 11 angiogenesis factors in patients
with HNC and correlated the levels with known prognostic factors
including the p16 status. In addition, we explored the effect of the
p16 status on the cellular source of angiogenesis factors in the
tumour tissue.
MATERIALS AND METHODS
Study population. Blood samples were obtained from 18 patients
with newly diagnosed HNC and 12 healthy controls. The
demographic details of patients and controls are provided in
Supplementary Table 1. Strict exclusion criteria were applied to
reduce the impact of other inflammatory conditions on the serum
levels of angiogenesis factors. Patients with co-existing inflamma-
tory disorders such as autoimmune diseases, diabetes, renal failure
and cardiac disease were excluded from the study. The study was
approved by the local research ethics committee and informed
consent was obtained from all study subjects.
Serum isolation and storage. Blood was allowed to coagulate for
at least 30min at room temperature and then centrifuged at 1500 g
for 10min and the serum was stored at a temperature below
 20 1C until analysis. In one HNC patient, plasma was used
instead of serum.
Multiplex analysis of cytokines. The multiplex Luminex Perfor-
mance angiogenesis panel was purchased from R&D Systems
(Abingdon, UK). The quantification of cytokines was performed
according to the manufacturer’s instructions using a Luminex
analyser. The following cytokines were analysed: VEGF, VEGF-D,
angiopoietin-1, angiogenin, thrombospondin-2, endostatin, placental
growth factor (PlGF), platelet-derived growth factor-aa (PDGF-aa),
platelet-derived growth factor-bb (PDGF-bb), fibroblast growth
factor-acidic (FGF-a) and fibroblast growth factor-basic (FGF-b).
Angiopoietin-1 and VEGF could not be quantified in the plasma
and therefore one HNC patient was excluded from those analyses.
Immunohistochemistry. The following primary antibodies were
used: rabbit polyclonal VEGF (A-20, Santa Cruz Biotechnology,
Heidelberg, Germany); goat polyclonal Angiopoietin-1 (R&D
Systems); and goat polyclonal Endostatin (R&D Systems). Paraffin
sections of tumour tissue were cut at 4 mm and heated for 45min at
60 1C before staining. Heat antigen retrieval was carried out using
Epitope Retrieval Solution 1 (VEGF and endostatin), pH 6 or
Epitope Retrieval Solution 2 (Angiopoietin-1), pH 9 at 100 1C for
20 or 30min, according to the antibody. Antibodies were diluted
1 : 50 and incubated for 15min. Negative controls used antibody
diluent in place of primary antibody. Visualisation for rabbit
polyclonal antibodies was carried out using the Bond Polymer
Refine kit (Leica Microsystems, Milton Keynes, UK), an HRP-
conjugated 3,30-diaminobenzidine (DAB) detection system, sup-
plied by Leica Microsystems. Visualisation for goat polyclonal
antibodies was carried out using the Bond Intense R kit, a Biotin/
streptavidin HRP-conjugated DAB detection system, supplied by
Leica Microsystems and secondary antibody-biotinylated rabbit
anti-goat, supplied by Dako UK Ltd (Ely, UK). All immuno-
histochemistry staining was carried out using Bond III Fully
automated staining system and associated reagents, supplied by
Leica Microsystems. Images were captured using an Olympus
BX50 microscope with UPlan Appo lenses and equipped with an
Olympus digital camera.
Statistical analysis. Data were compared using the Student’s
t-test. Probability values (P) of less than 0.05 were considered
statistically significant. Statistical analysis was performed using the
GraphPad Prism software version 5.02, Inc (GraphPad Software,
Inc., La Jolla, CA, USA).
RESULTS
Angiopoietin-1 is higher in the circulation of patients with
p16-negative HNC. Angiopoietins are a well-described family of
vascular growth factors that have a role in embryonic and tumour
angiogenesis (Suri et al, 1996; Holash et al, 1999). We examined
the levels of the pro-angiogenesis factor angiopoietin-1 in the
serum of HNC (n¼ 17) patients and healthy individuals (n¼ 13;
Figure 1). No significant differences were observed in the levels of
angiopoietin-1 when the total patient cohort was compared with
healthy individuals. However, further analysis revealed that
angiopoietin-1 levels in the circulation of patients with p16-
negative tumours were significantly higher compared with those
present in healthy individuals (Figure 1B). In contrast, serum
angiopoietin-1 levels in patients with p16-positive tumours did not
differ from healthy individuals (Figure 1B). We also examined
whether the tumour size or nodal status had any impact on the
circulating angiopoietin-1 level, neither of which was found to have
any influence (Figure 1C and D).
Vascular endothelial growth factor is higher in the circulation of
patients with p16-negative HNC. Vascular endothelial growth
factor is upregulated in several tumours and is a potent pro-
angiogenesis factor (Ferrara and Davis-Smyth, 1997; McMahon,
2000). We next evaluated the levels of circulating VEGF in
patients with HNC (n¼ 17) and healthy individuals (n¼ 13).
No differences in serum levels of VEGF were observed between
the total patient cohort and the healthy controls (Figure 2A).
However, in line with our observation with angiopoietin-1, the
levels of VEGF were significantly increased in patients with
p16-negative tumours compared with healthy individuals (Figure 2B).
Moreover, circulating VEGF levels in patients with p16-positive
tumours were comparable to those present in healthy individuals
(Figure 2B). In contrast to the p16 status, tumour and nodal stage
had no influence on circulating VEGF levels (data not shown).
Furthermore, whereas circulating levels of VEGF (total) showed a
difference between patients carrying p16-positive or -negative
tumours, no such difference was observed in VEGF-D levels
(Figure 2C and D).
Endostatin levels are higher in patients with HNC compared
with controls. We next examined the levels of circulating
endostatin in patients with HNC (n¼ 18) and healthy individuals
(n¼ 13). Endostatin is a fragment of collagen 18 and is a potent
anti-angiogenesis agent (O’Reilly et al, 1997). Endostatin was
found to be significantly higher in the serum of patients with HNC
compared with healthy individuals (Figure 3A). Unlike VEGF and
angiopoietin-1, a significant increase in endostatin was present in
both p16-negative and p16-positive HNC patients (Figure 3B). In
addition, tumour stage and nodal stage had no influence on
endostatin levels (not shown).
Levels of circulating thrombospondin-2, FGF-b, PDGF-aa,
PDGF-bb and PlGF in patients with p16-negative and
p16-positive HNC. In addition to the previously described
angiogenesis factors, we examined the levels of a panel of other
angiogenesis factors: thrombospondin-2, PlGF, PDGF-aa and
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PDGF-bb, FGF-b and angiogenin. Thrombospondin-2 is an
anti-angiogenesis factor (Iruela-Arispe et al, 2004). Whereas
thrombospondin-2 levels in the whole patient cohort (n¼ 18)
did not differ from controls (n¼ 13; Figure 4A), its levels were
found to be lower in sera from patients with p16-positive tumours
in comparison with the levels detected in healthy individuals or
patients with p16-negative tumours (Figure 4B). This, however, did
not reach statistical significance. Patients with T1/2 tumours had
lower levels of thrombospondin-2 compared with patients with
T3/4 tumours and healthy donors (Figure 4C), but again this did not
reach statistical significance. Serum levels of thrombospondin-2
were comparable in patients to N0 or node-positive disease
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Figure 2. VEGF levels in patients with HNC and controls. Circulating levels of VEGF were quantified using multiplex ELISA in sera from healthy
individuals (Ctrl, n¼13) and patients with HNC (n¼ 17). (A) The scatter plots show VEGF concentration in the two study groups (horizontal bars
show the mean value for each group). (B) VEGF levels were compared between p16-positive (HNC p16þ ) or p16-negative (HNC p16 ) HNC
patients and controls. *Po0.05. (C) The plots display VEGF-D in the two study groups. (D) The scatter plots display VEGF-D in p16-positive (HNC
p16þ ) and negative (HNC p16 ) patients and controls. VEGF¼ vascular endothelial growth factor.
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Figure 1. Angiopoietin-1 levels in patients with HNC and controls. Circulating levels of angiopoietin-1 were quantified using multiplex ELISA in
sera from healthy individuals (Ctrl, n¼13) and patients with HNC (n¼17). (A) The scatter plots show angiopoietin-1 concentration in the two study
groups (horizontal bars show the mean value for each group). (B) Angiopoietin-1 levels were compared between p16-positive (HNC p16þ ) or p16-
negative (HNC p16 ) HNC patients and controls. *Po0.05. (C) The plots display angiopoietin-1 in patients with early tumour stage (T1/2),
advanced tumour stage (T3/4) and controls. (D) The scatter plots display angiopoietin-1 in patients without nodal disease (N0), nodal disease (Nþ )
and controls.
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(Figure 4D). Levels of FGF-b, PDGF-aa, PDGF-bb and PlGF were
similar in HNC patients compared with the control group
(Figure 5A, C, E and G). In addition, the p16 status did not have
any influence on the levels of these angiogenesis factors (Figure 5B,
D, F and H). No differences were observed for angiogenin and
FGF-a (data not shown). A summary of all angiogenic factors is
included in Supplementary Table 2.
Tissue expression of VEGF differs between p16-positive and
p16-negative tumours. We next examined the expression of
angiopoietin-1, VEGF and endostatin in the HNC tumour tissue
using immunohistochemistry. Angiopoietin-1 was localised in
tumour tissue to both tumour cells and stromal cells (Figure 6A).
This pattern of expression of angiopoietin-1 was similar in both
p16-positive and p16-negative tumours. Strong VEGF expression
was noted in tumour cells and stromal cells in tissue specimens
from p16-negative tumours (Figure 6B left panel). In contrast,
expression of VEGF in p16-positive tissue was primarily localised
to stromal cells (Figure 6B right panel). Tumour cells in p16-
positive HNC tissue did not express VEGF in four out of five tissue
samples examined. We also examined endostatin in the tumour
tissue. Endostatin was expressed in stromal cells resembling
macrophages, whereas tumour cells in HNC did not express
endostatin. No differences were observed in the tissue expression of
endostatin in p16-positive or p16-negative tumour tissue.
DISCUSSION
This study explored the impact of the p16 status on the profile of
angiogenesis factors in HNC, both in terms of circulating levels of
these factors and their expression in the tumour tissue. We show
an interesting effect of the p16 status on angiogenesis factors in
HNC. First, the pro-angiogenesis factors VEGF and angiopoietin-1
are elevated in the serum of patients with p16-negative tumours
compared with healthy individuals, whereas this increase was not
observed in patients with p16-positive HNC. Second, we show via
immunohistochemistry that VEGF production in p16-positive
tumours is mainly derived from stromal cells while in p16-negative
tumours VEGF is produced both by tumour cells and stromal cells.
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Figure 3. Endostatin levels in patients with HNC and controls. Circulating levels of endostatin were quantified using multiplex ELISA in sera from
healthy individuals (Ctrl, n¼13) and patients with HNC (n¼18). (A) The scatter plots show endostatin concentration in the two study groups
(horizontal bars show the mean value for each group). (B) Endostatin levels were compared between p16-positive (HNC p16þ ) or p16-negative
(HNC p16 ) HNC patients and controls. ***Po0.001, **Po0.01, *Po0.05.
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Figure 4. Thrombospondin levels in patients with HNC and controls. Circulating levels of thrombospondin-2 were quantified using multiplex
ELISA in sera from healthy individuals (Ctrl, n¼ 13) and patients with HNC (n¼18). (A) The scatter plots show thrombospondin-2 concentration in
the two study groups (horizontal bars show the mean value for each group). (B) Thrombospondin-2 levels were compared between p16-positive
(HNC p16þ ) or p16-negative (HNC p16 ) HNC patients and controls. (C) The plots display thrombospondin-2 in patients with early tumour stage
(T1/2), advanced tumour stage (T3/4) and controls. (D) The scatter plots display thrombospondin-2 in patients without nodal disease (N0), nodal
disease (Nþ ) and controls.
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p16 is considered a good surrogate marker to identify HPV-
positive tumours and is widely used in clinical practice. It has been
reported that p16 status correlates with a better prognosis in
oropharyngeal cancers (Weinberger et al, 2004). In addition, a
good correlation between HPV positivity and p16 status has been
demonstrated in oropharyngeal cancers (Nichols et al, 2009),
which form the majority of our patient cohort (15 of 18 patients).
However, detection of p16 by immunohistochemistry carries a
false-positive rate of 3–4% as some HPV-negative tumours could
continue to express p16 (Schlecht et al, 2011; Thavaraj et al, 2011;
Seiwert, 2013). Although detection of HPV using PCR is the most
accurate test for identifying HPV infection, p16 expression using
immunohistochemistry continues to be a widely accepted method
for HPV detection due to low costs and availability of technical
infrastructure in most head and neck units. Of note, ongoing
clinical trials such as De-ESCALaTE HPV stratify patients for
inclusion on the basis of the HPV status as determined by p16
immunohistochemistry (Masterson et al, 2014). Interestingly,
whereas the p16 status does not correlate with HPV positivity in
HNC outside the oropharynx such as the oral tongue, it still
associates with a better prognosis irrespective of the HPV status
(Harris et al, 2011).
It is well established that patients with HPV-positive tumours
fare better than patients with HPV-negative tumours (Ang et al,
2010). This has resulted in discussion of altering therapy (de-
escalation) of HPV-positive tumours by reducing the dose of
radiation or trials of cetuximab rather than cisplatin in an effort to
reduce the side effects of chemoradiation therapy (Masterson et al,
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Figure 5. Other angiogenic factor levels in patients with HNC and controls. Circulating levels of angiogenic factors were quantified using
multiplex ELISA in sera from healthy individuals (Ctrl, n¼ 13) and patients with HNC (n¼ 18). (A) The scatter plots show FGF-b concentration in
controls and HNC patients. Horizontal bars show the mean value for each group. (B) FGF-b levels in p16-positive (HNC p16þ ) or p16-negative
(HNC p16 ) HNC patients and controls. (C) The scatter plots show PDGF-aa concentration in controls and HNC patients. (D) PDGF-aa levels in
p16-positive or p16-negative HNC patients and controls. (E) The scatter plots show PDGF-bb concentration of controls and HNC patients.
(F) PDGF-bb levels in p16-positive or p16-negative HNC patients and controls. (G) The scatter plots show PlGF concentration controls and HNC
patients. (H) PlGF levels in p16-positive or p16-negative HNC patients and controls. FGF-b¼ fibroblast growth factor-basic; PDGF¼platelet-
derived growth factor; PlGF¼placental growth factor.
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2014; Tornesello et al, 2014). However, the precise reasons for the
different biological behaviours of HPV-positive vs HPV-negative
tumours are not certain. Our findings that VEGF and angiopoie-
tin-1 levels are raised in the serum of patients with p16-negative
tumours but not those with p16-positive tumours indicates that
differences in angiogenic pathways may account, at least in part,
for the distinct biological behaviour of p16-positive HNC.
The tumour stroma has emerged as an important contributor to
the angiogenesis and progression of cancer (Semenza, 2013). Our
immunohistochemistry analysis confirms the important role of the
stroma in the production of angiogenesis factors in the HNC
microenvironment. Stromal cells such as macrophages are known
to produce angiogenesis factors such as VEGF (Lin and Pollard,
2007). We demonstrate that in p16-positive tumour tissue the
stromal cells are the predominant source of VEGF, with no
expression of VEGF in tumour cells. In contrast, in p16-negative
tumours both tumour and stromal cells produce VEGF. This
suggests that future work into the mechanisms of VEGF induction
in stromal cells vis-a-vis tumour cells may reveal novel strategies to
specifically target stromal-derived VEGF. Although our results
need to be validated in a larger patient cohort, our findings may
have therapeutic potential. Indeed, anti-VEGF antibodies have
been used as adjuvants to chemotherapy in the treatment of HNC
(Cohen et al, 2009) but are unfortunately associated with
potentially fatal complications such as haemorrhage and high
blood pressure (Qi et al, 2013; Peng et al, 2014). Inhibitors specific
for tumour stromal cell-derived VEGF could allow for inhibition of
angiogenesis within p16-positive HNC while leaving normal
vasculature intact and avoiding catastrophic side effects.
Our results have also uncovered interesting facets of endostatin,
which is an anti-angiogenesis factor that has been shown to be
elevated in a variety of cancers (Koc et al, 2006; Kantola et al,
2014). We also found significantly elevated levels of endostatin in
our HNC patient cohort, albeit there was no difference between
p16-positive and p16-negative tumours. We found that endostatin
is expressed in tumour stroma in cells resembling macrophages. To
our knowledge, this is the first demonstration of endostatin
production within the cancer stromal tissue, which warrants
further investigation to define the role of endostatin in the tumour
microenvironment. Recombinant endostatin therapy has shown
good response in mouse models in early studies (Blezinger et al,
1999), but human tumour response was not encouraging (Thomas
et al, 2003), possibly due to a failure to achieve adequate local
concentrations of endostatin required to inhibit tumour growth.
Endostatin delivery to tumour tissue using viral vectors is currently
in trials (Ye et al, 2014).
The p16 status was also not found to have an impact on the
production of other angiogenesis factors such as FGF-b, PDGF and
PlGF. However, thrombospondin-2 levels showed a trend to be
lower in the serum of patients with p16-positive tumours
compared with patients with p16-negative tumours and even
healthy donors (not statistically significant). High levels of
thrombospondin-2 in lung cancer have been correlated to poorer
prognosis (Naumnik et al, 2015), whereas downregulation of
thrombospondin-2 in gastric cancer correlates with poorer
prognosis (Sun et al, 2014). The relationship between thrombos-
pondin-2 and p16 status is not clear currently, but future work
could shed light on this.
In summary, alterations in angiogenesis pathways in p16-
positive vs p16-negative HNC could be one of the factors
underlying the different biological behaviour of these two types
of HNC. Future studies in larger patient cohorts and direct
demonstration of HPV using PCR techniques within tumour tissue
will provide further confirmation of the role of HPV in this
process. In addition, the identification of stromal cells as important
producers of angiogenesis factors, in particular VEGF and
endostatin, opens new avenues for research on targets for selective
inhibition or induction of angiogenesis factors from stromal cells
in HNC.
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Figure 6. Expression of angiopoietin-1, VEGF and endostatin in p16-
negative and p16-positive HNC tissue. Expression of angiogenic
factors (angiopoietin-1, VEGF and endostatin) was assessed in tissue
from five patients with p16-negative and five patients with p16-positive
HNC using immunohistochemistry (see Materials and Methods for
details). (A) Angiopoietin-1 expression in tumour cells (arrow heads)
and tumour stroma (arrows). (B) VEGF expression in tumour tissue
(arrow heads) and stromal tissue (arrows). (C) Expression of endostatin
in the tumour stroma (arrows). (D) p16 staining in the tumour tissue
used for analysis of angiogenesis factor expression.
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